BAF155 MUTANT GENE AND PHARMACEUTICAL USE THEREOF

WIPO Patent Application WO/2023/236864

A1

Provided in the present invention are a BAF155 mutant gene and the pharmaceutical use thereof. Provided in the present invention are a BAF155 mutant or an active fragment thereof. Compared with wild-type BAF155, the BAF155 mutant or the active fragment thereof contains a mutation of K948. The present invention further provides a pharmaceutical composition, the pharmaceutical composition comprising the BAF155 mutant or the active fragment thereof. Further provided in the present invention is the use of the BAF155 mutant or the active fragment thereof or the pharmaceutical composition in preparation of drugs for preventing or treating cardiac remodeling. The applicants have found that BAF155 interacts with the BRCT domain of PARP1, and BAF155-K948R is ubiquitinated to modify the PARP1 and cooperates with SIRT2 to prevent cardiac remodeling, thus providing a new thinking and research direction for treatment and prevention of cardiovascular diseases.

WO/2001/092526	HUMAN KCNQ5 POTASSIUM CHANNEL, METHODS AND COMPOSITIONS THEREOF
JPH06510036	INDUSTRIAL APPLICABILITY The composition and method for the treatment of cystic fibrosis.
WO/1988/010120	TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS

SUN YINGXIAN (CN)
ZHANG NAIJIN (CN)
ZHANG YING (CN)

PCT/CN2023/098024

December 14, 2023

June 02, 2023

Click for automatic bibliography generation  

SUN YINGXIAN (CN)
ZHANG NAIJIN (CN)
ZHANG YING (CN)

C07K14/47; A61K38/17; A61P9/00; A61P9/04; C12N15/12

WO2021081032A1	2021-04-29
WO2011106442A1	2011-09-01
WO2021055489A1	2021-03-25
WO2021176008A1	2021-09-10

CN114989287A	2022-09-02
CN114920816A	2022-08-19
US20200206344A1	2020-07-02

SHENYANG PATENT & TRADEMARK AGENCY ACADEMIA SINICA (CN)

View/Download PDF      PDF Help

Previous Patent: DEACETYLATION MODIFIED BAF155 PROTEIN AND PHARMACEUTICAL USE THEREOF

Next Patent: HOLDER SUPPORTING BASE, AND HOLDER